| pubmed-article:6747835 | rdf:type | pubmed:Citation | lld:pubmed |
| pubmed-article:6747835 | lifeskim:mentions | umls-concept:C1280551 | lld:lifeskim |
| pubmed-article:6747835 | lifeskim:mentions | umls-concept:C0025519 | lld:lifeskim |
| pubmed-article:6747835 | lifeskim:mentions | umls-concept:C0036071 | lld:lifeskim |
| pubmed-article:6747835 | lifeskim:mentions | umls-concept:C0005508 | lld:lifeskim |
| pubmed-article:6747835 | lifeskim:mentions | umls-concept:C1512045 | lld:lifeskim |
| pubmed-article:6747835 | pubmed:issue | 1 | lld:pubmed |
| pubmed-article:6747835 | pubmed:dateCreated | 1984-8-29 | lld:pubmed |
| pubmed-article:6747835 | pubmed:abstractText | The dose-dependent first-pass metabolism and pharmacokinetics of salicylamide (SAM) were studied at four dose levels in six dogs. Four minutes after each oral dose, a tracer dose of [14C]SAM was given i.v. to determine clearance and bioavailability. Over the dosage range studied, 5 to 40 mg/kg, bioavailability increased from 0.24 +/- 0.14 (mean +/- S.D.) to 0.76 +/- 0.20 (P less than .05). Clearance decreased from 3.4 +/- 1.0 to 0.60 +/- 0.11 liters/min (P less than .01) and half-life increased from 5.0 +/- 1.2 to 23.5 +/- 6.1 min (P less than .01). Measurement of SAM clearance to individual metabolites indicated that the sulfoconjugation and not the glucuronidation pathway was responsible for the dose-dependent effects observed. These effects occurred even at doses not expected to have caused significant depletion of body stores of inorganic sulfate; the plasma concentration of inorganic sulfate decreased by only a maximum of 13 and 26% after the 5- and 10-mg/kg SAM doses, respectively. When [14C]SAM was given alone in tracer amounts, clearance values greatly exceeded cardiac output. This suggests that SAM undergoes sulfation in organs other than the liver and intestinal wall. | lld:pubmed |
| pubmed-article:6747835 | pubmed:grant | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6747835 | pubmed:language | eng | lld:pubmed |
| pubmed-article:6747835 | pubmed:journal | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6747835 | pubmed:citationSubset | IM | lld:pubmed |
| pubmed-article:6747835 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6747835 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6747835 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6747835 | pubmed:chemical | http://linkedlifedata.com/r... | lld:pubmed |
| pubmed-article:6747835 | pubmed:status | MEDLINE | lld:pubmed |
| pubmed-article:6747835 | pubmed:month | Jul | lld:pubmed |
| pubmed-article:6747835 | pubmed:issn | 0022-3565 | lld:pubmed |
| pubmed-article:6747835 | pubmed:author | pubmed-author:TozerT NTN | lld:pubmed |
| pubmed-article:6747835 | pubmed:author | pubmed-author:PondS MSM | lld:pubmed |
| pubmed-article:6747835 | pubmed:author | pubmed-author:RubinG MGM | lld:pubmed |
| pubmed-article:6747835 | pubmed:author | pubmed-author:EffeneyD JDJ | lld:pubmed |
| pubmed-article:6747835 | pubmed:author | pubmed-author:WaschekJ AJA | lld:pubmed |
| pubmed-article:6747835 | pubmed:author | pubmed-author:FieldingR MRM | lld:pubmed |
| pubmed-article:6747835 | pubmed:author | pubmed-author:CouetW RWR | lld:pubmed |
| pubmed-article:6747835 | pubmed:issnType | Print | lld:pubmed |
| pubmed-article:6747835 | pubmed:volume | 230 | lld:pubmed |
| pubmed-article:6747835 | pubmed:owner | NLM | lld:pubmed |
| pubmed-article:6747835 | pubmed:authorsComplete | Y | lld:pubmed |
| pubmed-article:6747835 | pubmed:pagination | 89-93 | lld:pubmed |
| pubmed-article:6747835 | pubmed:dateRevised | 2007-11-14 | lld:pubmed |
| pubmed-article:6747835 | pubmed:meshHeading | pubmed-meshheading:6747835-... | lld:pubmed |
| pubmed-article:6747835 | pubmed:meshHeading | pubmed-meshheading:6747835-... | lld:pubmed |
| pubmed-article:6747835 | pubmed:meshHeading | pubmed-meshheading:6747835-... | lld:pubmed |
| pubmed-article:6747835 | pubmed:meshHeading | pubmed-meshheading:6747835-... | lld:pubmed |
| pubmed-article:6747835 | pubmed:meshHeading | pubmed-meshheading:6747835-... | lld:pubmed |
| pubmed-article:6747835 | pubmed:meshHeading | pubmed-meshheading:6747835-... | lld:pubmed |
| pubmed-article:6747835 | pubmed:meshHeading | pubmed-meshheading:6747835-... | lld:pubmed |
| pubmed-article:6747835 | pubmed:meshHeading | pubmed-meshheading:6747835-... | lld:pubmed |
| pubmed-article:6747835 | pubmed:meshHeading | pubmed-meshheading:6747835-... | lld:pubmed |
| pubmed-article:6747835 | pubmed:meshHeading | pubmed-meshheading:6747835-... | lld:pubmed |
| pubmed-article:6747835 | pubmed:meshHeading | pubmed-meshheading:6747835-... | lld:pubmed |
| pubmed-article:6747835 | pubmed:year | 1984 | lld:pubmed |
| pubmed-article:6747835 | pubmed:articleTitle | Dose-dependent bioavailability and metabolism of salicylamide in dogs. | lld:pubmed |
| pubmed-article:6747835 | pubmed:publicationType | Journal Article | lld:pubmed |
| pubmed-article:6747835 | pubmed:publicationType | Research Support, U.S. Gov't, P.H.S. | lld:pubmed |
